STAT+ subscribers can sign up here to get it delivered to their inbox. The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars.

The Supreme Court of California is gearing up to decide an important question for the future of product liability law: Do drug manufacturers have ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and ...

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.

With an array of new medicines and medical devices on display global medical companies are looking to tap further into the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences (GILD) has been one of the most searched ... During this period, the Zacks Medical - Biomedical and Genetics industry, which Gilead falls in, has lost 1.9%. The key question ...

Gilead’s Q3 sales increased 7% year-over-year, including 13% year-over-year growth for Biktarvy. The Liver Disease portfolio sales increased 4% to $733 million, and Veklury sales increased 9% ...

Gilead Sciences (GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from its COVID revenues and spurring investor anticipation for new products ...

In a report released yesterday, Tyler Van Buren from TD Cowen maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price target of $95.00. Tyler Van Buren’s rating is ...

Gilead Sciences GILD will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Gilead Sciences to ...